BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8976819)

  • 41. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
    Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
    Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
    Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
    Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
    Thomas HD; Porter DJ; Bartelink I; Nobbs JR; Cole M; Elliott S; Newell DR; Calvert AH; Highley M; Boddy AV
    Br J Clin Pharmacol; 2002 Jan; 53(1):83-91. PubMed ID: 11849199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
    Siddik ZH; Newell DR; Boxall FE; Harrap KR
    Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
    Dittrich C; Sevelda P; Baur M; Marth C; Hudec M; Vavra N; Grunt T; Fazeny B; Salzer H
    Cancer; 1993 May; 71(10):3082-90. PubMed ID: 8490836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic evaluation of zeniplatin in humans.
    DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
    Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita).
    Filippich LJ; Charles BG; Sutton RH; Bucher AM
    Aust Vet J; 2004 Jun; 82(6):366-9. PubMed ID: 15267096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
    Dorr RT; Lagel K; McLean S
    Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
    Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    Shaw LM; Bonner HS; Brown DQ
    Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amifostine (Ethyol): dosing, administration and patient management guidelines.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S46-9. PubMed ID: 8976823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.